Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Fineline Cube Mar 18, 2026
Company Deals

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Fineline Cube Mar 18, 2026
Company Deals

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Fineline Cube Mar 18, 2026
Company Deals

Kintor Pharma Partners with Chicmax to Accelerate KT‑939 Commercialization – Active Cosmetic Ingredient Targets Whitening Market

Fineline Cube Mar 18, 2026
Company Deals

PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma – Exclusive China Partnership for Weekly GLP‑1 Diabetes Drug

Fineline Cube Mar 17, 2026
Policy / Regulatory

China Unveils NHSA Grassroots Healthcare Reform – 14‑Point Guidance Targets RMB Fund Flow Shift to Primary Care Institutions

Fineline Cube Mar 17, 2026
Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Fineline Cube Mar 18, 2026
Company Drug

Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer

Fineline Cube Mar 18, 2026
Company Medical Device

Asieris’ Uro-G Bladder Endoscope Catheter Awaits NMPA Approval

Fineline Cube Feb 22, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...

Company Deals

Merck KGaA Partners with Beijing for Drug Imports via Beijing Ports

Fineline Cube Feb 22, 2023

Merck KGaA (ETR: MRK), a leading German pharmaceutical company, has struck a partnership with the...

Company Drug

Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials

Fineline Cube Feb 22, 2023

China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...

Company Deals

Meihua International Partners with Hainan for Medical Tech Park and R&D Center

Fineline Cube Feb 22, 2023

Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), a specialist in Chinese medical consumables, has...

Company Deals

Kactus Biosystems and Levinthal Biotech Deepen Strategic Partnership

Fineline Cube Feb 22, 2023

Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a...

Drug Policy / Regulatory

CDE Releases 67th Batch of Chemical Generic Reference Preparations

Fineline Cube Feb 22, 2023

The Center for Drug Evaluation (CDE) has released the 67th batch of chemical generic reference...

Drug

CDE Releases Guidelines for Chemically Synthesized Peptide Research

Fineline Cube Feb 22, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Pharmaceutical Research of...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study

Fineline Cube Feb 21, 2023

Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...

Company Deals

Abbott Partners with Sinopharm for Expanded Medical Solutions in China

Fineline Cube Feb 21, 2023

US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical...

Company Drug

Luoxin’s Tegoprazan Gains NMPA Review for Duodenal Ulcer Treatment

Fineline Cube Feb 21, 2023

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has...

Company Drug

Shanghai Pharmaceuticals’ X842 Accepted for NMPA Review for Reflux Esophagitis

Fineline Cube Feb 21, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...

Company Deals Medical Device

We-Linking Raises Tens of Millions in Angel Round for Brain-Computer Interface

Fineline Cube Feb 21, 2023

We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly...

Company Deals

Hybio Pharma and CR Medicine Collaborate on Market Expansion

Fineline Cube Feb 21, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot...

Company Drug

Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi

Fineline Cube Feb 21, 2023

Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...

Company Drug

Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy

Fineline Cube Feb 21, 2023

Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the...

Company Drug

Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023

Fineline Cube Feb 21, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...

Company Deals

Beijing Huashen Shengdian Secures Angel Funding for Pelvic Surgery Monitor R&D

Fineline Cube Feb 21, 2023

China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly...

Company Drug

Zhaoke’s Generic Bimatoprost + Timolol Maleate Eye Drops Approved in China

Fineline Cube Feb 21, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment

Fineline Cube Feb 21, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s...

Company R&D

Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs

Fineline Cube Feb 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...

Posts pagination

1 … 530 531 532 … 636

Recent updates

  • Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development
  • Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug
  • Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets
  • Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform
  • Pfizer Reports Positive FOURLIGHT-1 Results for Atirmociclib – CDK4 Inhibitor Shows PFS Benefit in Post-CDK4/6 Breast Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Jiuyuan Gene Engineering Secures NMPA Approval for JY47 – SIRPα Antibody Enters MASH Clinical Development

Company Deals

Alebund Pharma Licenses AP306 to R1 Therapeutics – USD 100 Million Deal for First‑in‑Class Hyperphosphatemia Drug

Company Deals

Ark Biopharma Files Hong Kong IPO – Roche‑Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets

Company Deals

Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical – RMB 200 Million Deposit for 14‑Product APAC Commercial Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.